Posts

The Weekly Recap 5/1/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, secure funding, launch partnerships, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2). Avatar Medical Received FDA 510(k) clearance for Avatar Medical Vision, its software platform for instant 3D medical image processing, review, and surgical planning, enabling commercialization in the U.S. This clearance also establishes compatibility with the Barco Eonis 3D glasses-free display, forming the foundation of Eonis Vision, a joint solution that aims to bring clinicians and patients together around a shared, real-time view of anatomy during consultations. Axoft Raised an oversubscribed $55M Series A led by C.P. Group Innovation, with participation from Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. The company will use the funds to expand global clinical trials, advance U.S. regu...
Post a Comment
Read more

The Weekly Recap 5/8/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive regulatory approvals, launch partnerships, achieve clinical milestones, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2). APEX Biologix Welcomed LSI Alumni Jeff Cambra to its Board of Directors. Cambra brings extensive experience across the medical device and therapeutics industry, with leadership roles spanning general management, sales, marketing, and product development, along with experience supporting commercialization strategy, portfolio management, and strategic transactions. Aqua Medical Announced 12-month follow-up clinical data outside the U.S. for its proprietary radiofrequency vapor ablation platform, highlighting the potential of its proximal intestinal mucosal ablation procedure as a durable treatment for type 2 diabetes. Results showed up to a 2.6% reduction in HbA1c, 100% elimination of exogenous insulin in treated patients, 80% rema...
Post a Comment
Read more

The Weekly Recap 5/15/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, launch partnerships, receive regulatory approvals, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2). Adialante Granted its second U.S. patent covering the core technology behind its ability to image in MRIs using radio waves. The company is developing a new class of mobile MRI systems designed to deliver diagnostic-quality imaging directly to practices without the need for construction or major capital investment. Angelini Ventures Welcomed Samantha Wong, PhD, as Investment Analyst. Dr. Wong played a key role in the launch of EspressoLab by Angelini Ventures and the establishment of the company’s Singapore office. Apreo Health Announced the appointment of LSI Alumni David Amerson to its Board of Directors and a strategic investment from OSF Ventures, the corporate investment arm of OSF HealthCare. Amerson has over 30 years of leadership...
Post a Comment
Read more

The Weekly Recap 5/22/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, launch partnerships, receive regulatory approvals, and much more on the road to LSI Asia ‘26 in Singapore (June 30 - July 2). Activ Surgical Partnered with Medical Dynamics to be the company’s exclusive distribution partner in Belgium, the Netherlands, and Luxembourg for ActivSight™. ActivSight Intelligent Light is the first and only modular form-factor with multimodal Advanced Visualization, allowing surgeons to augment their senses using augmented reality overlays. Adagio Medical Submitted PMA application to the FDA for its vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia in patients with ischemic or non-ischemic structural heart disease. The submission is supported by the FULCRUM-VT pivotal IDE trial, which enrolled 209 patients and demonstrated 97.4% acute clinical success, 84.3...
Post a Comment
Read more

The Memo: Paradromics Advancing Brain-Computer Interfaces to Restore Communication

Under the direction of Founder and CEO Matt Angle, Paradromics is advancing a high-data-rate brain-computer interface (BCI) designed to restore communication for people with severe motor impairments by translating neural signals directly into speech, text, and computer control. Origin Story Paradromics was founded to address a clear gap between academic promise and real-world usability in BCIs. Early systems demonstrated compelling proof of concept but lacked the performance and durability required for clinical deployment. “We saw that while brain-computer interfaces had demonstrated incredible proof of concept in clinical research, they were limited by low data rates, poor long-term performance, and bulky through-skin connectors. They weren’t ready for deployment as robust products,” Angle explained. With early support from DARPA, the team set out to build what Angle describes as “broadband for the brain,” focusing on high-channel-count systems capable of recording from large populati...
Post a Comment
Read more

The Memo: Nami Surgical Unlocking the Future of Ultrasonic Surgery

Under the direction of CEO Nikki Palfrey and Co-Founder and COO Nico Fenu, PhD, Nami Surgical is developing a meaningful new capability in robotic-assisted surgery: integrated ultrasonic advanced energy with wristed articulation. Built on deep expertise in ultrasonics and designed specifically for robotic integration, the company is working to address a functional gap that has persisted as surgical robotics has scaled, creating a platform intended to bring the speed, precision, and safety advantages of ultrasonic energy into a new generation of procedures. Origin Story Nami Surgical was founded in December 2021 by Dr. Nico Fenu and Dr. Rebecca Cleary, both alumni of the University of Glasgow’s Centre for Medical and Industrial Ultrasonics, the world’s largest academic ultrasonic engineering unit. The company emerged directly from Fenu’s PhD research, as well as the founders’ work within the Ultrasurge: Surgery Enabled by Ultrasonics program, giving Nami a foundation rooted in speciali...
Post a Comment
Read more

BCI Market: Following the Capital Into Neurotechnology’s Next Frontier

It has been a quieter stretch across medtech headlines, with recent editions focused heavily on M&A and portfolio reshuffling. This week, we are shifting attention to a segment that continues to attract outsized investor interest relative to its stage of development: the BCI market. As Q1 2026 wrapped, one signal stood out clearly in recent funding data. Capital is increasingly flowing toward companies developing brain-computer interface platforms. The scale of recent financings demonstrates that trend. Merge Labs launched out of stealth with a $252 million Seed round in January. Science Corp. followed with a $230 million Series C in March. That same month, Stairmed raised $73 million with backing from Tencent and Alibaba, while Gestala secured $21.6 million. These rounds build on earlier financings, including $200 million for Synchron and $650 million for Neuralink. This level of investment is notable given that no BCI device has yet reached commercial approval in the United State...
Post a Comment
Read more